Crossmark

The transcription factor Rfx7 limits metabolism of NK cells and promotes their maintenance and immunity

Crossref DOI link: https://doi.org/10.1038/s41590-018-0144-9

Published Online: 2018-07-02

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Castro, Wilson

Chelbi, Sonia T. https://orcid.org/0000-0003-3465-6537
Niogret, Charlène

Ramon-Barros, Cristina

Welten, Suzanne P. M.

Osterheld, Kevin

Wang, Haiping

Rota, Giorgia

Morgado, Leonor

Vivier, Eric https://orcid.org/0000-0001-7022-8287
Raeber, Miro E. https://orcid.org/0000-0003-2609-0246
Boyman, Onur

Delorenzi, Mauro https://orcid.org/0000-0001-7631-3263
Barras, David

Ho, Ping-Chih https://orcid.org/0000-0003-3078-3774
Oxenius, Annette

Guarda, Greta https://orcid.org/0000-0001-9243-6116
License Information

Text and Data Mining valid from 2018-07-02
More Information

Article History

Received: 21 August 2017

Accepted: 20 April 2018

First Online: 2 July 2018

Competing Interests

: E.V. is a cofounder, shareholder, and employee of Innate Pharma. Unrelated projects in the laboratory of G.G. are supported by OM-Pharma, Galenica, and the Novartis Foundation. Three unrelated projects in the laboratory of P.-C.H. are supported by Roche and Idorsia. O.B. is a shareholder in Anaveon AG. An unrelated project in the group of M.D. is supported by Merck KGaA, and M.D. owns stocks from the companies Novartis, Roche, and Idorsia. The other authors have no conflicting financial interest to declare.